Dear Healthcare Providers,
Effective July 10, 2023, Anti-cyclic citrullinated peptide (Anti-CCP) in-house testing will resume at LifeLabs and will be performed on the Roche Cobas e801 platform.
While the clinical performance of the assay remains unchanged, the reported values will be different from our previous assay. The new cut-off for a positive result is 17 U/mL. Interpretive comments will accompany each result, as shown in the following table:
|
Anti-CCP value (U/mL) |
Interpretation |
|
<17 |
Negative: A negative CCP antibody result does not exclude rheumatoid arthritis (RA) as this test is reportedly negative in approximately 25% of RA patients. |
|
≥17 |
Positive: CCP antibodies are highly specific (96%) for rheumatoid arthritis (RA) and usually occur early in the disease process, sometimes before full clinical manifestation of RA. |
There is no change on test requisition forms. For further information, please do not hesitate to contact myself or the LifeLabs Customer Care Centre at 1-877-849-3637.
Sincerely,
|
William E. Schreiber MD Clinical Director of Chemistry, BC Professor | Dept of Pathology & Lab Medicine, UBC LifeLabs | 3680 Gilmore Way | Burnaby, BC V5G 4V8 T 604-412-4483 | C 604-842-8228 |
|
